Pulmonary function in asbestos cement workers: a dose-response study

M FINKELSTEIN

From the Health Studies Service, Ontario Ministry of Labour, Toronto, Ontario M7A 1T7, Canada

ABSTRACT This study has found that residence time weighted exposure (asbestos dose) may be used to model the risk and extent of pulmonary function abnormalities in a cohort of asbestos cement workers. This parameter, which incorporates both exposure concentration and latency, had previously proved useful for modelling the risk of radiographic abnormalities in this cohort. Asbestos dose and smoking were independent and additive contributors to decreased pulmonary function. It was also found that lung function results could be used as surrogates for dose in the assessment of mortality risk in this cohort.

In a previous paper it was noted that asbestos disease may develop or progress after exposure has ceased, and that the usual measure of exposure, the “cumulative exposure,” suffers from the shortcoming that its value remains fixed once exposure has ended, requiring that both cumulative exposure and time enter explicitly into risk assessment. It was shown that an alternative measure called “dose” (which is the sum of the annual asbestos exposure weighted by the retention time) could be used to model the risk of certain radiographic abnormalities in a cohort of asbestos cement workers, and that when using this measure, the assessment of risk had the desirable property of being independent of the time of evaluation over the interval 20–34 years from first exposure.

The present study was performed to assess whether “dose” might also be useful in describing the development of pulmonary function abnormalities in this cohort. This measure was found to provide descriptions of the relations between exposure to asbestos and physiological abnormality that were independent of the time of assessment, and it is concluded that dose—that is, the residence time weighted exposure—might be generally useful in describing the relations between exposure to fibrogenic dusts and the risk of disease.

Materials and methods

STUDY POPULATION

Men eligible for inclusion in the study were production workers hired before 1960 who had been employed for nine years or more and who had worked at least 12 months in occupations with exposure to asbestos. When six men who had died before the start of pulmonary function testing in 1970 were excluded, 180 men met the criteria for inclusion; of these, 138 (77%) had at least one set of measurements available. Many had been tested several times and 52 had been tested on ten or more occasions.

Table 1 gives the numbers of men who had measurements at various intervals from first exposure (latency). After analysis had indicated that the dose-response pattern was independent of latency a “master” cohort was assembled by selecting one set of measurements from each of the 138 men. The demography of this master cohort is also given in Table 1.

EXPOSURE AND DOSE ESTIMATION

Information about the factory and the estimation of individual exposures by extrapolation from personal membrane filter measurements has been published. Asbestos dosages were calculated by assuming that a fixed proportion of the workplace air concentrations was deposited in the lungs and each year’s accumulation was weighted by the residence time in lung tissue (the formula used is given in the appendix). The units for dose are fibres/ml × years squared (f/ml × y²).

Cumulative exposures had previously been estimated to be accurate to within a factor of three to five; since the formula used to calculate dose weights early exposures most heavily, the dose estimates used here are probably more uncertain than the estimates of cumulative exposure.
SMOKING INFORMATION
Smoking information had been requested by pulmonary function technicians at the time of examination. Additional information was obtained by questionnaire and from physicians’ records. For the purposes of this study, smokers were defined as men who had smoked cigarettes later than 10 years from first exposure; non-smokers were defined as men who had never smoked or who had stopped before 10 years from first exposure. For most of the analyses in this paper, smoking was treated as a dichotomous variable.

PULMONARY FUNCTION TESTING (PFT)
All measurements were made either as part of routine surveillance of the workforce or as part of the assessment for workers’ compensation claims; none was made specifically for epidemiological purposes. A mobile laboratory from the Occupational Chest Disease Service of the Ontario Ministry of Labour made biannual visits to the plant and performed a standard spirometric evaluation yielding values for forced vital capacity (FVC) and forced expiratory volume in the first second of expiration (FEV₁). All volumes were corrected to BTPS. Compensation examinations were performed in the laboratory of the Chest Disease Service and a more elaborate assessment, including the measurement of static lung volumes and exercise testing, was performed. In addition to FVC and FEV₁ the tests selected for analysis in this study include total lung capacity (TLC), the single breath carbon monoxide diffusing capacity (uncorrected for haemoglobin concentration) (DLCO), and DLCO per unit lung volume (KCO).

The reference equations of Knudson et al and Morris et al were used to make comparisons with populations of healthy non-smoking men. Because volumes predicted by these equations frequently differ, comparisons were made with both. The reference equation of Miller et al was used for diffusion tests.

STATISTICAL METHODS
The relations between PFT results and various explanatory variables were assessed by multiple linear regression with examination of residuals. Cox proportional hazard regression analysis was used to study PFT results as prognostic factors for mortality.

Results
LATENCY DEPENDENCE OF THE DOSE-RESPONSE RELATIONS
The relations between pulmonary function results and the explanatory variables age, height, smoking, and dose were explored by use of multiple linear regression. As noted in table 1 each man provided measurements in one or more latency periods and dose-response relations could be calculated separately for each interval. To test whether these relations differed among latency intervals, all the data were pooled and linear regression analyses were performed using “indicator variables” to specify to which interval each measurement belonged. The results indicated that the temporal terms did not add significantly to the fit of the models; the null hypothesis that the dose-response relations were the same in all intervals was thus not rejected. This finding is illustrated for FVC in fig 1 in which, for ease of presentation, the data have been grouped in four dose categories.

Because the relation between dose and response was effectively independent of the time of assessment,
one set of measurements was chosen from each of the 138 workers who had data available and a pooled "master cohort" was created to provide the largest data set for subsequent analysis. Where possible, the values used were averages over the three consecutive years showing the least variability and with the greatest latency. Since there were relatively few measurements of diffusing capacity, the latency independence of diffusion could not be tested; it was assumed that the dose-response relations for diffusion would also be effectively independent of latency and the master cohort was also used for the analysis of this measure.

Three regression models were used to examine the relations between PFT results and the explanatory variables. In the first model the PFT value itself served as the dependent variable; in the two other analyses comparisons were made with the reference equations using proportional (\% predicted) and difference (observed-predicted) models. The results for FVC and FEV1 are presented in table 2. Both FVC and FEV1 decreased significantly with increasing dose, about 4\% of predicted per 1000 fibres/ml × y2, and because of the similarity of response their ratio, \( \text{FEV}_1 / \text{FVC} \), was independent of dose. Smokers had lower values of both FVC and FEV1 and the contributions of smoking and dose to decreased pulmonary function were additive. This is shown in table 3, which shows that when the regression analyses were run separately for the smokers and non-smokers the dose coefficients were similar. Figure 2 shows the relation between FVC (observed-predicted) and dose; the considerable variability in the data is clearly shown.

The diffusion results are presented in table 4. Asbestos dose was associated with significantly lower
Pulmonary function in asbestos cement workers: a dose-response study

Table 3  Relations between pulmonary function and dose for the smokers and non-smokers.* (Numbers in parentheses are estimates of the 95% confidence intervals)

<table>
<thead>
<tr>
<th></th>
<th>FVC</th>
<th>FEV1</th>
<th>FVC %</th>
<th>FEV1 %</th>
<th>TLC†</th>
<th>DLCO†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smokers</td>
<td>−1.4 × 10⁻⁴ultur</td>
<td>−1.1 × 10⁻⁴</td>
<td>−3.3 × 10⁻³</td>
<td>−3.9 × 10⁻³</td>
<td>−0.8 × 10⁻⁴</td>
<td>+1.1 × 10⁻⁴</td>
</tr>
<tr>
<td>(n = 43)</td>
<td>(−2.8, −0.1)</td>
<td>(−2.2, 0)</td>
<td>(−6.1, −0.4)</td>
<td>(−7.4, −0.5)</td>
<td>(−2.9, +1.3)</td>
<td>(−11.2, +13.4)</td>
</tr>
<tr>
<td>Smokers</td>
<td>−1.9 × 10⁻⁴</td>
<td>−1.2 × 10⁻⁴</td>
<td>−4.0 × 10⁻³</td>
<td>−3.5 × 10⁻³</td>
<td>−2.5 × 10⁻⁴</td>
<td>−9.9 × 10⁻⁴</td>
</tr>
<tr>
<td>(n = 95)</td>
<td>(−2.8, −1.0)</td>
<td>(−2.0, −0.4)</td>
<td>(−6.0, −2.0)</td>
<td>(−5.9, −1.0)</td>
<td>(−4.1, −0.9)</td>
<td>(−18.5, −1.3)</td>
</tr>
</tbody>
</table>

*Units of dose are fibres/ml × y².
†For TLC and DLCO the number of non-smokers was 26 and the number of smokers was 53.

Table 4  Regression coefficients from multiple linear regression analyses for diffusion

<table>
<thead>
<tr>
<th></th>
<th>Constant</th>
<th>Age</th>
<th>Height</th>
<th>Smoking</th>
<th>Dose</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLCO (ml/min/mm Hg)</td>
<td>31.4</td>
<td>−0.14</td>
<td>NS</td>
<td>−3.27</td>
<td>−6.7 × 10⁻⁴</td>
<td>0.19</td>
</tr>
<tr>
<td>(n = 83)</td>
<td>(−6.2, +69.1)</td>
<td>(−0.26, −0.01)</td>
<td>NS</td>
<td>(−5.49, −1.05)</td>
<td>(−13.6, +0.2)</td>
<td>0.11</td>
</tr>
<tr>
<td>DLCO (% predicted)</td>
<td>84.3</td>
<td>NS</td>
<td>NS</td>
<td>(−11.2)</td>
<td>(−1.8 × 10⁻³)</td>
<td>0.31</td>
</tr>
<tr>
<td>(Miller)</td>
<td>(75.3, 93.3)</td>
<td>NS</td>
<td>NS</td>
<td>(−19.0, −3.4)</td>
<td>(−43.2, +0.5)</td>
<td>0.11</td>
</tr>
<tr>
<td>TLC (l)</td>
<td>−7.5</td>
<td>NS</td>
<td>0.079</td>
<td>−2.2 × 10⁻⁴</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>(n = 79)</td>
<td>(−15.0, −0.03)</td>
<td>(0.04, 0.12)</td>
<td>NS</td>
<td>(−3.5, −0.9)</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>KCO (ml/min/mm Hg/l)</td>
<td>8.9</td>
<td>−0.024</td>
<td>NS</td>
<td>NS</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>(n = 79)</td>
<td>(3.2, 14.6)</td>
<td>(0.04, −0.005)</td>
<td>NS</td>
<td>NS</td>
<td>0.11</td>
<td></td>
</tr>
</tbody>
</table>

Table 5  Proportion of men with test results less than the lower limit of normal*%

<table>
<thead>
<tr>
<th></th>
<th>0&lt;1200</th>
<th>1200&lt;2400</th>
<th>2400&lt;3600</th>
<th>3600&lt;4800</th>
<th>≥4800</th>
<th>Test for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean dose</td>
<td>840</td>
<td>1800</td>
<td>2950</td>
<td>4090</td>
<td>5960</td>
<td></td>
</tr>
<tr>
<td>FVC: unadjusted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knudson et al</td>
<td>7/37</td>
<td>10/47 (21%)</td>
<td>12/35 (34%)</td>
<td>3/9 (33%)</td>
<td>6/10 (60%)</td>
<td></td>
</tr>
<tr>
<td>Morris et al</td>
<td>11/37 (30%)</td>
<td>15/47 (32%)</td>
<td>17/35 (49%)</td>
<td>5/9 (56%)</td>
<td>7/10 (70%)</td>
<td></td>
</tr>
<tr>
<td>FVC: smoking adjusted</td>
<td>3/37 (8%)</td>
<td>9/47 (19%)</td>
<td>11/35 (31%)</td>
<td>3/9 (33%)</td>
<td>6/10 (60%)</td>
<td></td>
</tr>
<tr>
<td>Knudson et al</td>
<td>7/37 (19%)</td>
<td>12/47 (26%)</td>
<td>13/35 (37%)</td>
<td>5/9 (56%)</td>
<td>7/10 (70%)</td>
<td></td>
</tr>
<tr>
<td>Morris et al</td>
<td>4/37 (11%)</td>
<td>5/47 (11%)</td>
<td>10/35 (29%)</td>
<td>0/9 (0%)</td>
<td>3/10 (30%)</td>
<td></td>
</tr>
<tr>
<td>FEV1: smoking adjusted</td>
<td>3/37 (8%)</td>
<td>9/47 (17%)</td>
<td>14/35 (40%)</td>
<td>4/9 (44%)</td>
<td>5/10 (50%)</td>
<td></td>
</tr>
<tr>
<td>Knudson et al</td>
<td>7/37 (19%)</td>
<td>7/47 (15%)</td>
<td>13/35 (37%)</td>
<td>3/9 (33%)</td>
<td>6/10 (60%)</td>
<td></td>
</tr>
<tr>
<td>Morris et al</td>
<td>6/37 (16%)</td>
<td>7/47 (15%)</td>
<td>12/35 (34%)</td>
<td>0/9 (0%)</td>
<td>5/10 (50%)</td>
<td></td>
</tr>
<tr>
<td>DLCO: smoking adjusted</td>
<td>4/37 (11%)</td>
<td>5/47 (11%)</td>
<td>10/35 (29%)</td>
<td>0/9 (0%)</td>
<td>3/10 (30%)</td>
<td></td>
</tr>
<tr>
<td>Miller et al</td>
<td>4/12 (33%)</td>
<td>7/26 (27%)</td>
<td>8/27 (30%)</td>
<td>3/8 (38%)</td>
<td>5/10 (50%)</td>
<td></td>
</tr>
</tbody>
</table>

*Units of dose are fibres/ml × y².

Fig 3  Proportion of abnormal values of FVC against dose, adjusted for smoking, and 5% abnormality rate in reference population. Error bars are estimates of 95% confidence limits.

Values for TLC and was of borderline statistical significance for decreased diffusing capacity. Smokers had significantly lower results for DLCO, but not for TLC. Once again, all dose-smoking interaction terms were non-significant.

Relation between dose and abnormal pulmonary function

The dose-response analysis presented in the previous section investigated the relation between dose and pulmonary function each measured on a continuous scale; an alternative approach is to classify each measurement as either normal or abnormal. One method of defining abnormality is by selecting as the lower limit of normal (LLN) the lower 95% confidence limit (or fifth centile) of measurements from healthy, non-smoking reference populations such as those of Knudson et al or Morris et al.³ ⁴ Thus for the present
study the LLN was taken to be the predicted value minus 1.645 \times \text{the standard error of the reference equation.}

To assess the relation between dose and the prevalence of abnormalities the men were divided among dose categories 1200 f/ml \times y^2 wide. As a graphical analysis showed that the rate of abnormality in each interval was essentially independent of latency the master cohort was used for the detailed analysis. To adjust for any smoking differences among dose categories the average volumes lost by smokers, derived from the regression analyses of the previous section, were added to the measured values of the smokers: 0.21 for FVC; 0.32 for FEV\textsubscript{1} and 3.3 ml/min/mm Hg for DLCO. The results are given in table 5 with, and without, the adjustment for smoking. The reference equations of Knudson et al\textsuperscript{3} and Morris et al\textsuperscript{4} predict different LLN and this has an impact on the classification of abnormality.

For both FVC and FEV\textsubscript{1} the prevalence of abnormalities increased significantly with dose, but an effect could not be shown for DLCO. Tests for departure from a linear trend\textsuperscript{7} were non-significant. Finney presents an equation that may be used to adjust the observed proportions for the 5% abnormality rate in the reference populations (see appendix),\textsuperscript{8} and this adjustment has been used in fig 3 which displays the prevalence of abnormalities of FVC against dose.

**PULMONARY FUNCTION—RADIOGRAPHIC CORRELATIONS**

Radiographs, many of them serial, were available for all but two members of the master cohort and had been interpreted according to the 1971 ILO classification scheme by a NIOSH certified "B" reader before the gathering of the pulmonary function data.\textsuperscript{9} For the analysis of pulmonary function—radiographic correlations, the film closest in time (within two to three years) to the pulmonary function test used in the master cohort analysis was selected. Men were grouped according to the scores for profusion of small irregular opacities and bilateral pleural thickening and mean values for PFT were computed. The results are presented in table 6 which shows that there was a trend for the average PFT results to worsen as the radiographic appearance.

---

**Table 6** Relation between radiographic codes* and pulmonary function results

<table>
<thead>
<tr>
<th>Radiographic code</th>
<th>0/0</th>
<th>0/1</th>
<th>1/0</th>
<th>1/1</th>
<th>≥ 1/2</th>
<th>No pleural thickening</th>
<th>Pleural thickening</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of men</td>
<td>75</td>
<td>13</td>
<td>9</td>
<td>31</td>
<td>8</td>
<td>101</td>
<td>35</td>
</tr>
</tbody>
</table>

FVC: % Predicted

No < LLN\textsuperscript{†}

76.2 (n = 32)

No < LLN

12 (38%)

4 (50%) | 4 (44%) | 12 (46%) | 7 (88%) | 20 (37%) | 18 (62%) |

*Radiographic codes are for small irregular opacities and bilateral pleural thickening.

†LLN is the lower limit of normal: 1.65 standard errors below the predicted value.

---

**Table 7** Results of Cox regression mortality analysis for 115 men entering observation at 20–24 years latency

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All causes (n = 40)</td>
</tr>
<tr>
<td>FVC (β)\textsuperscript{†}</td>
<td>p &lt; 0.001 (−0.50)</td>
</tr>
<tr>
<td>FEV\textsubscript{1} (β)\textsuperscript{†}</td>
<td>p &lt; 0.001 (−0.50)</td>
</tr>
<tr>
<td>FEV\textsubscript{1}/FVC</td>
<td>NS</td>
</tr>
<tr>
<td>X-ray ≥ 1/1</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>Multivariate models\textsuperscript{‡}</td>
<td>FVC (p &lt; 0.04)</td>
</tr>
</tbody>
</table>

\*Myocardial infarction.

\(\beta\) is the regression coefficient.

NS = Not significant.

*Mesothelioma, lung, gastrointestinal.

\†FVC and FEV\textsubscript{1} are expressed in terms of a Z-score: observed-predicted/standard error of the reference equations of Knudson et al.\textsuperscript{3}

\‡In the multivariate models age, smoking, x-ray, and FVC were entered simultaneously. There was no correlation between FVC and age.
worsened; there was, however, no association between FEV₁/FVC, an index of airways obstruction, and the radiographic codes. Men with bilateral pleural thickening had lower PFT results than men without, but this appears to be due to the correlation between pleural thickening and parenchymal opacities; among the 75 men who had a score of 0/0 for small opacities there was no significant difference between the PFT results of the 12 men with bilateral pleural thickening and the 63 men without. In a complementary analysis men were grouped according to the results of their PFTs and mean values for the radiographic codings were computed; again PFT and radiographic results tended to worsen together. It was noted, however, that some men with normal results in one test technique had abnormalities in the other.

PULMONARY FUNCTION—MORTALITY CORRELATIONS

One hundred and fifteen men had pulmonary function testing at 20–24 years latency. A Cox regression analysis was used to investigate whether the test results were prognostic factors for subsequent mortality. The results for FVC, FEV₁, and FEV/FVC were expressed as Z-scores (observed-predicted/standard error of the reference equation of Knudson et al³) and tested for association with mortality in both univariate and multivariate models that also included age, smoking, and x ray (≥1/1) as predictor variables. Table 7 gives the results.

Decreased FVC and FEV₁ were significantly associated with all cause mortality and with death from asbestos associated cancers. FVC and FEV₁ are highly correlated and the regression coefficients, 0, are similar. In the Cox model relative risk is given approximately by eβ; taking β = -0.5 (and with the standard error for FVC being 600 ml) then the relative risk of death for individuals with FVC 600 ml less than predicted is e-0.5 = 1.6 and for individuals with FVC at the lower limit of normal it is e-0.5 × 1.65 = 2.3. The presence or absence of small irregular opacities on the chest radiograph provided no additional prognostic information beyond that contained in FVC except for death from myocardial infarction.

Discussion

The aim of this study was to determine whether asbestos “dose,” a new measure of exposure incorporating information about both dust concentrations and latency, would prove useful in modelling the risk and extent of pulmonary function abnormalities in a cohort of asbestos cement workers. An earlier study of the cohort had found this parameter to be useful in describing the risk of small irregular opacities on the chest radiograph⁴ and the present analysis indicates that it is also valuable for functional abnormalities. It was determined that the dose-response relations were independent of the time of assessment over the time interval 20–34 years from first exposure and so this one parameter, dose, may be used to model disease risk, rather than the two, cumulative exposure and time, that would otherwise be required.

The analysis was performed with data from 138 (77%) of the 180 men who met the criteria for entry to the study. The others had left employment before the initiation of routine pulmonary function testing in 1970 and had neither returned for follow up nor filed claims for workers’ compensation. It would be expected that, because of the widespread publicity given to asbestos disease in Ontario, most former employees with significant disease would have established compensation claims; the lung function of those lost to follow up is thus likely, on average, to be no worse than that of workers with similar dosages who were included in the analysis. Since the dosages of those lost to follow up were, on average, less than those of the men included in the analysis, the effect of any bias due to selective entry into the study would be to underestimate the mean test results at the lower end of the dose range and to underestimate the slope of the dose-response curves. Since the intercepts for FVC and FEV₁ (% predicted) in the multiple regression analyses are close to 100%, this bias is unlikely to be large.

Workers at this factory were exposed to dusts of chrysotile and crocidolite asbestos, silica, and cement. Silica is generally regarded as producing little functional abnormality unless silicosis progresses beyond the simple nodular stage.¹⁰ ¹¹ Irwig and Rocks found that silicosis had no effect on FVC in gold miners but that there was a relation between exposure to dust in gold mines and symptoms and lung function tests indicative of chronic obstructive lung disease.¹² Similarly, Kalac found no decrease in FVC among cement workers, but did find changes in the FEV₁/FVC ratio suggestive of obstructive impairment.¹³ ¹⁴ Since the exposure related changes in the present study were of a restrictive rather than an obstructive pattern, assessment of the asbestos effect is unlikely to be substantially confounded by exposure to the other components of the dust cloud. Conceivably the clearance of asbestos might be altered by concurrent exposure to the other dusts, but this possibility could not be assessed.

The pattern of abnormalities observed in this cohort was similar to that generally described among asbestos workers—namely, a dose related reduction in vital capacity, total lung capacity, and carbon monoxide diffusing capacity.¹⁰ There was no evidence of obstructive disease beyond that attributable to smoking. Begin and colleagues have presented evi-
dence of small airways obstruction among non-smoking employees of the Quebec asbestos mining industry, but detection of these changes required an advanced physiological assessment and they were not detectable by routine spirometry.15

Two different models were used to explore the relation between asbestos dose and abnormality of lung volumes. In the proportional model asbestos dosage was presumed to cause a loss in the "per cent of predicted" volume. Since the predicted volume depends on the age and height of the worker, the actual volume lost when the per cent predicted declines may differ among workers accumulating the same dose. In the difference model asbestos dosage produces a loss of volume that is independent of the predicted volume. Intuitively, it would seem that a given dosage of asbestos should not produce the same loss of volume among men differing in size and age and that the proportional model should be preferable; nevertheless in the present analysis both models fit the data equally well and one could not be selected as preferable to the other.

The effects of smoking and asbestos were independent and additive in this cohort. Abnormalities attributed to smoking were similar to those reported in the smoking health effects reports. Krumholz and Hedrick studied a group of middle aged executives with a mean age of 47 and a mean height of 179 cm.16 Smokers had lower mean values for VC (300 ml), FEV1 (375 ml), and DLCO (5 ml/min/mm Hg) than non-smokers. Edelman and colleagues studied another group of white collar workers.17 For men aged 50 and 176 cm in height, smokers had lower values for VC (200 ml) and FEV1 (170 ml). In the present study in which the mean age was 58 and the mean height 174 cm the differences were found to be 200 ml for FVC, 320 ml for FEV1, and 3.3 ml/min/mm Hg for DLCO. When an estimate was made of pack-years (P-Y) consumption for each man, the loss in FEV1 was found to be 8 ml/P-Y. This compares well with the 8 ml/P-Y reported by Speizer et al18 and the 11 ml/P-Y among current smokers and 7 ml/P-Y among ex-smokers reported by Beck and colleagues.19

In the present analysis the data were compatible with linear asbestos dose-response relations. When account was taken of smoking habit, a loss of FVC of 170 ml (or 4% of predicted) per 1000 f/ml × y2 was attributable to asbestos exposure. Significant dose related trends were found for the prevalence of abnormalities of FVC and FEV1. For carbon monoxide diffusing capacity, a dose-response relation was found only among the smokers (table 3) and the prevalence of abnormalities did not vary significantly with dose (table 5). Several other studies have failed to find clear trends in diffusing capacity with exposure.20 21 One of

the hallmarks of advanced disease is a decreased diffusing capacity,10 and it may be that in epidemiological studies a trend is obscured by uncertainties in measurement and exposure assignment.

Many epidemiological studies have shown that death rates among asbestos exposed workforces vary with exposure. For most workers quantitative estimates of asbestos exposure will not be available; in this circumstance it might be helpful if the results of clinical tests could be used as surrogates for exposure estimates and if prognostic assessments could be made according to the results. It was shown previously that in this cohort of asbestos cement workers the profusion of small irregular opacities on the chest radiograph was a prognostic factor.9 In the present analysis pulmonary function was also found to have prognostic value with individuals having an FVC at the lower limit of normal estimated to have a risk of death raised twofold compared with individuals whose results were the same as those predicted by the reference equation of Knudson.3 Since radiographic and PFT results are correlated, the question of whether any additional information could be obtained by considering both together was assessed in a multivariate Cox regression model. Only for the case of death from myocardial infarction did the radiographic result provide prognostic information beyond that contained in FVC, and for this cause of death there was no association between FVC and risk. The association between radiographic abnormality and death from infarction in this cohort is possibly due to chance; however, Liddell and McDonald noted an association between the presence of small opacities and the risk of death from diseases of the heart among Quebec asbestos workers so the association may be a true one.22

In conclusion, this study found that the use of residence time weighted exposure as a measure of asbestos dose provided estimates of the dose-response relations of various pulmonary function tests that were independent of latency over the interval 20–34 years from first exposure. An earlier study of the same cohort found that the same dose measure could be used to model the risk of radiographic abnormalities and might be useful for modelling mesothelioma rates. It thus appears that this one parameter, dose, could replace the two, cumulative exposure and time, which are otherwise required to model dose-response relations in the pneumoconioses. Verification of this hypothesis in other cohorts exposed to fibrogenic dusts would be of interest.

Appendix

(1) The formula used to calculate dose:
Pulmonary function in asbestos cement workers: a dose-response study

\[ D(T) = \sum_{i=1}^{T} C(t_i) (T-t_i) \]

Where \( D(T) \) is the dose in the year \( T \) and \( C(t_i) \) is the average exposure in the year \( t_i \).

(2) The adjustment of prevalence for background occurrence:

\[ P = \frac{P^* - C}{1 - C} \]

Where \( P^* \) is the observed prevalence at dose \( D \)

\( C \) is the prevalence in an unexposed population (here 5%)

\( P \) is the adjusted prevalence.

References